Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High dose AMBISOME on a fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: a Phase 3 randomised controlled non-Inferiority trial

Next Previous
Trial Profile

High dose AMBISOME on a fluconazole backbone for cryptococcal meningitis induction therapy in sub-Saharan Africa: a Phase 3 randomised controlled non-Inferiority trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amphotericin B liposomal (Primary) ; Amphotericin B; Fluconazole; Flucytosine
  • Indications Cryptococcal meningitis
  • Focus Therapeutic Use
  • Acronyms AMBITION; Ambition-cm; Ambition-P3

    • Most Recent Events

    • 06 Mar 2024 Results of study on stored plasma and CSF samples from the AMBITION trial evaluating whether CrAgSQ can predict outcomes presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024
    • 08 Mar 2022 The aim of this study is to find out whether a single high dose of L-AmB is as effective as the standard treatment in terms of preventing deaths from cryptococcal meningitis hence I have indexed trial focus as TU.
    • 21 Jul 2021 Primary endpoint (All-cause mortality within the first 10 weeks after randomisation (non-inferiority)) has been met as per results presented at the 11th International AIDS Society Conference on HIV Science
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top